Their expression in prostate tumors is related with disease progression and metastasis [24], whereas MMP9 was shown to increase growth factors bioavailability and to elicit epithelial-to-mesenchymal transition in tumor cells [25,26], therefore promoting an aggressive phenotype. This evidence concerns the gene MMP9 and prostate neoplasm.